- December 1, 2011
LAVAL, QC and ATHENS , Greece , Dec. 1, 2011 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that it has signed an exclusive license and distribution agreement (the "Agreement") with ...
- November 28, 2011
OVOS Natural Health Inc. launches VIVIMIND™ in Canada
CALGARY , Nov. 28, 2011 /CNW Telbec/ - OVOS Natural Health Inc. ("OVOS"), a wholly-owned subsidiary of Advanced Orthomolecular Research Inc. ("AOR") and AOR's exclusive Canadian partner, BELLUS Health Inc. (TSX: BLU) ("BELLUS Health"), ...
- November 9, 2011
LAVAL, QC, Nov. 9, 2011 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the third quarter ended September 30, 2011 . ...
- August 10, 2011
BELLUS Health reports results for second quarter ended June 30, 2011
Patient recruitment progressing for KIACTA ™ Confirmatory Phase III Clinical Trial LAVAL, QC, Aug. 10, 2011 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results ...
- June 8, 2011
BELLUS HEALTH REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2011
Patient recruitment on-going for KIACTA ™ Confirmatory Phase III Clinical Trial LAVAL, QC, June 8, 2011 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results ...
- May 11, 2011
BELLUS HEALTH DELIVERING ON KEY STRATEGIC PARTNERSHIPS AND KIACTA™ PHASE III DEVELOPMENT
Updates provided at Annual and Special Meeting of Shareholders LAVAL, QC, May 11 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") held its Annual Meeting of Shareholders ...
- April 7, 2011
BELLUS HEALTH ISSUES SHARES IN FINAL PAYMENT FOR THE EXERCISE OF ITS LEASE TERMINATION OPTION
LAVAL, Qc, April 7 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") announced today that it issued approximately 34.2 million common shares of the Company to A.R.E. Quebec No. 2, Inc. ...
- April 4, 2011
BELLUS HEALTH AND THE AGAHAN GROUP ENTER INTO BROAD LICENSE FOR VIVIMIND™ IN THE MIDDLE EAST
LAVAL, QC, April 4 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that it has signed an exclusive license and distribution agreement (the "Agreement") with Agahan Ayandeye Pars Inc. ...
- March 31, 2011
Strategic initiatives to reduce burn rate now fully implemented LAVAL, QC, March 31 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") today announced that it has ...
- February 23, 2011
BELLUS HEALTH REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2010
LAVAL, QC, Feb. 23 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the fourth quarter and year ended December 31, 2010 . All currency figures ...
- January 31, 2011
Prodrug demonstrates improved gastrointestinal tolerability and pharmacokinetic profile over tramiprosate LAVAL, QUEBEC , Jan. 31 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or ...
- January 14, 2011
BELLUS HEALTH EXERCISES OPTION TO TERMINATE LEASE
Lease termination will result in annual savings of approximately $4.5 million LAVAL, QC, Jan. 14 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS ...
- January 4, 2011
ADVANCED ORTHOMOLECULAR RESEARCH ACQUIRES BELLUS HEALTH'S CANADIAN SUBSIDIARY OVOS NATURAL HEALTH
AOR is granted exclusive distribution rights to VIVIMIND ™ in Canada ; BELLUS Health retains all rights to VIVIMIND ™ in other jurisdictions worldwide LAVAL, QC and CALGARY , Jan. 4 /CNW Telbec/ - BELLUS Health Inc. (TSX: ...
- December 15, 2010
LAVAL, QC, and NEW YORK, Dec. 15 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ ...
- November 10, 2010
LAVAL, QC, Nov. 10 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the third quarter ended September 30, 2010 . All currency figures reported ...
- October 19, 2010
BELLUS HEALTH AND FB HEALTH ENTER AGREEMENT FOR BELLUS' VIVIMIND™ IN ITALY
FB Health to move rapidly to launch VIVIMIND™ in Italy LAVAL, QC, Oct. 19 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) through its subsidiary, BELLUS Health (International) Limited ("BELLUS ...
- October 6, 2010
BELLUS HEALTH ANNOUNCES APPOINTMENT OF MARTIN TOLAR, M.D., Ph.D. TO ITS BOARD OF DIRECTORS
LAVAL, QC, Oct 6 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") is pleased to announce the appointment of Martin Tolar , M.D., Ph.D., to the Board of Directors of the Company, ...
- September 30, 2010
HEALTH CANADA GRANTS VIVIMIND™ A NATURAL HEALTH PRODUCT NUMBER
VIVIMIND™, a natural health product for the brain, is formally authorized for sale in Canada LAVAL,QC, Sept. 30 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS ...
- August 9, 2010
Bellus Health reports results for second quarter ended June 30, 2010
Announcement of new initiatives to reduce burn rate LAVAL, QC, Aug. 9 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the second quarter ended June 30, 2010 . The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified. Financial Results ...
- May 12, 2010
Annual Meeting of Shareholders - BELLUS Health provides update on corporate and product developments
LAVAL, QC, May 12 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") held its Annual and Special Meeting of Shareholders today. President and Chief Executive Officer Roberto Bellini provided shareholders with updates on the Company's new development-focused business model, on the status of products in the development pipeline, on VIVIMIND(TM) and on the finances of the Company. "I am pleased to lead BELLUS Health into its next business phase," said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "Our new development-focused business model emphasizes what the Company does best: bringing products from the pre-clinical phase through proof-of-concept Phase II studies. "In collaboration with our partner Celtic Therapeutics, we are advancing our product candidate KIACTA(TM) through a Phase III clinical trial at no development cost to BELLUS Health. In addition, we are targeting the development of a prodrug for Alzheimer's disease. We are optimistic that our expertise and experience in this field will help us succeed. ...
BELLUS Health reports results for first quarter ended March 31, 2010
LAVAL, QC, May 12 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") reported today its financial results for the first quarter ended March 31, 2010 . "The last few months have been satisfying for BELLUS Health as we advanced the products in our pipeline while continuing to focus on controlling costs," said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "Our new partnership with Celtic Therapeutics on KIACTA(TM) and the advancement of NRM8499 development program for the treatment of Alzheimer's disease demonstrate the value in our product pipeline. Also, our decision to discontinue trials on NC-503 (eprodisate) for the treatment of Type II diabetes due to lack of efficacy in the Phase II clinical trial enables us to focus our finances more readily on projects that create value for shareholders," he added. Financial Results ...
/R E P E A T -- BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010/
LAVAL, QC, May 11 /CNW Telbec/ - Dr. Francesco Bellini , Chairman of BELLUS Health Inc. (TSX: BLU), invites all shareholders to attend the Annual and Special Meeting of Shareholders to be held on Wednesday, May 12, 2010 at 10:00 a.m. in the Maxwell-Cummings Auditorium of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379 Sherbrooke Street West, Montreal , Quebec . About BELLUS Health BELLUS Health is a global health company focused on the research and development of products to provide innovative health solutions to address critical unmet medical needs. For further information, please visit www.bellushealth.com . ...
- May 11, 2010
BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010
LAVAL, QC, May 11 /CNW Telbec/ - Dr. Francesco Bellini , Chairman of BELLUS Health Inc. (TSX: BLU), invites all shareholders to attend the Annual and Special Meeting of Shareholders to be held on Wednesday, May 12, 2010 at 10:00 a.m. in the Maxwell-Cummings Auditorium of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379 Sherbrooke Street West, Montreal , Quebec . About BELLUS Health BELLUS Health is a global health company focused on the research and development of products to provide innovative health solutions to address critical unmet medical needs. For further information, please visit www.bellushealth.com . ...
- May 4, 2010
BELLUS Health ends NC-503 diabetes development program following results
LAVAL, QC, May 4 /CNW Telbec/ - BELLUS Health (TSX: BLU) announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint. "While we are disappointed that the NC-503 indication for Type 2 Diabetes did not prove to be effective, our decision today enables us to preserve shareholder value and conserve our financial and human resources for projects that we believe have high potential for success," said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. About NC-503 (eprodisate disodium) ...
- April 29, 2010
BELLUS Health and Celtic Therapeutics enter agreement for BELLUS' drug candidate KIACTA(TM)
KIACTA(TM) advancing to a confirmatory Phase III clinical trial LAVAL, QC, April 29 /CNW Telbec/ - BELLUS Health (TSX: BLU) and Celtic Therapeutics announced today that they have signed a final agreement pursuant to which Celtic Therapeutics will acquire and license worldwide rights related to the Phase III investigational product candidate KIACTA(TM) (eprodisate) for upfront payments of US$10 million, and will fund 100% of KIACTA(TM)'s development costs through its confirmatory Phase III clinical study and other development activities, estimated at US$20 million. KIACTA(TM) is being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. Celtic Therapeutics will complete the Phase III study and all other requirements for KIACTA(TM)'s regulatory approval. Celtic Therapeutics will then conduct an auction process for the commercialization rights of KIACTA(TM). The overall proceeds of the auction process are expected to be shared equally between the parties. "We are pleased to deliver today on what has been a major priority of our Company by announcing a partnership to develop KIACTA(TM) to its fullest potential. With its extensive expertise in drug development and preparation of regulatory filings, we believe Celtic Therapeutics is the ideal partner for the KIACTA(TM) program," said Mr. Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "I am very proud of the pioneering work that the BELLUS Health team has accomplished to date towards the advancement of this important program and we look forward to collaborating with Celtic Therapeutics to help realize the development and full commercial breadth of KIACTA(TM), a product that has the potential to benefit so many patients suffering from this terrible disease. This transaction confirms our strong belief that there is substantial value in the BELLUS Health product portfolio and strengthens our financial position," he concluded. ...
- April 1, 2010
LAVAL, QC, April 1 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company") announced today that, on March 30, 2010 , the Company initiated a Phase I clinical study for NRM8499, a prodrug of tramiprosate. NRM8499 is intended for the treatment of Alzheimer's disease. The randomized, double-blind, placebo-controlled study will investigate the safety, tolerability and pharmacokinetic profile of NRM8499 in a group of up to 84 young and elderly healthy subjects. NRM8499 was previously identified by BELLUS Health as a compound which increases the brain exposure to tramiprosate. Preclinical studies conducted in rodents showed that NRM8499 increased plasma and brain exposure to tramiprosate by 1.5 to 3 fold. The Company believes that an increase in the exposure of tramiprosate to the brain may help improve the therapeutic effect on cognitive function and other clinical outcomes in Alzheimer's disease. "We are very excited about the launch of the NRM8499 Phase I clinical study. The knowledge acquired through the tramiprosate development program concerning this compound, along with our enhanced understanding of Alzheimer's disease acquired through more than 15 years of preclinical and clinical research in this field, leads us to believe that the potential for NRM8499 is extremely promising," said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "We are looking forward to the results of the study which could eventually lead to the development of the first disease-modifying treatment for Alzheimer's disease," he concluded. ...
- February 24, 2010
BELLUS Health reports results for fourth quarter and year ended December 31, 2009
LAVAL, QC, Feb. 24 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) (the "Company") reported today its financial results for the fourth quarter and year ended December 31, 2009 . All currency figures reported in this press release, including comparative figures, are in US dollars, unless otherwise specified. "We continue to focus on effectively developing and adding value to the products in our pipeline," said Roberto Bellini , President and Chief Executive Officer. The Company continues to be extremely cost-conscious and our substantially reduced loss in 2009 reflects that vigilance." For the fourth quarter ended December 31, 2009 , the Company recorded a net loss of $5,360,000 ( $0.03 per share), compared to $11,136,000 ( $0.22 per share) for the corresponding quarter the previous year. For the year ended December 31, 2009 , the net loss amounted to $8,227,000 ( $0.06 per share), compared to a net loss of $48,095,000 ( $0.97 per share) for the same period last year. ...
- December 15, 2009
MONTREAL , Dec. 15 /CNW Telbec/ - The Board of Directors of BELLUS Health Inc. (the "Company") (TSX: BLU) is pleased to announce that Mr. Roberto Bellini has been named President and Chief Executive Officer of BELLUS Health, effective January 1, 2010 . Mr. Bellini graduated from McGill University in Biochemistry and was most recently, Vice President, Business Development at BELLUS Health. He has 8 years of experience with the Company's products, science, and the industry in which it operates. This experience provides him with a unique ability and the insight required to move the Company forward in its next phase of development. As previously announced at the annual general meeting of shareholders in June 2009 , Dr. Francesco Bellini is stepping down as President and Chief Executive Officer of the Company effective December 31, 2009 . Dr. Bellini will remain Chairman of the Board of Directors and will also provide ongoing advisory services to the Company, thus enabling BELLUS Health to continue to benefit from his vast expertise and knowledge of the health sciences and the pharmaceutical industries. "I am honoured by this appointment by the Board and wish to thank them for their support and for this opportunity. Through this expanded role, and together with the Company's leadership team and its employees, I look forward to contributing to the Company's success by building on its core strengths to move the Company's innovative products forward, and to building significant shareholder value," said Roberto Bellini . ...
- November 10, 2009
BELLUS Health reports results for third quarter of fiscal 2009
LAVAL, QC, Nov. 10 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) (the Company) reports financial results for the third quarter and nine-months ended September 30, 2009 . The Company reported a reduced net loss, compared to the corresponding period in the previous year, and an increased cash position for the quarter, due largely to Management's efforts to reduce overhead expenses and its cash burn rate, as well as a successful rights offering during the third quarter. Quarterly Highlights: The following highlights and financial results should be read in conjunction with the company's financial statements, notes to the financial statements, and Management's Discussion and Analysis for the third quarter and nine-month period ended September 30, 2009 . These documents will be available in the coming days on the Company's web site at www.BellusHealth.com , and on SEDAR at www.sedar.com . ...
- September 8, 2009
BELLUS Health announces results of rights offering
Company to present at the Rodman and Renshaw 11th Annual Healthcare Conference LAVAL, QC, Sept. 8 /CNW Telbec/ - BELLUS Health Inc. ("BELLUS Health" or ...
- August 11, 2009
BELLUS Health reports results for first half of fiscal 2009
LAVAL, QC, Aug. 11 /CNW Telbec/ - BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) reported results for the second quarter and first half ended June 30, 2009. All currency figures reported, including comparative ...
- July 16, 2009
ECUBLENS, SWITZERLAND, July 16 /CNW Telbec/ - BELLUS Health (International) Limited, a wholly owned subsidiary of BELLUS Health Inc. (BELLUS Health, TSX: BLU), today announced that the Italian Ministry of Health ...
- July 15, 2009
BELLUS Health Inc. Announces Record Date for $12 Million Rights Offering To Common Shareholders
LAVAL, QC, July 15 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) today announced that it has set August 5, 2009, as the record date for its previously announced C$12,080,018 rights offering to holders of its common ...
- July 7, 2009
BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders
Signs Standby Purchase Agreement for $8 million Company Announces VP, Finance LAVAL, QC, July 7 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) today ...
- July 6, 2009
Tramiprosate North American Phase III Clinical Study Results Published in Journal of Nutrition, Health and Aging LAVAL, QC, July 6 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) announces ...
- June 5, 2009
BELLUS Health Inc. Announces Officer
LAVAL, QC, June 5 /CNW Telbec/ - BELLUS Health Inc. (TSX:BLU) announces that, following its Annual General Meeting held yesterday, the Board of Directors has approved the appointment of Mr. Roberto Bellini to the position ...
- June 4, 2009
LAVAL, QC, June 4 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) (BELLUS Health or the Company) held its Annual General Meeting of Shareholders today, where management provided shareholders with updates on the status of ...
- June 2, 2009
BELLUS Health Inc. Annual General Meeting of Shareholders June 4, 2009
LAVAL, QC, June 2 /CNW Telbec/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of BELLUS Health Inc. (TSX: BLU), invites all shareholders to attend the Annual General Meeting of Shareholders ...
- May 6, 2009
BELLUS Health reports results for first quarter of fiscal 2009
LAVAL, QC, May 6 /CNW Telbec/ - BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) reported results for the first quarter ended March 31, 2009. The Company reported a net loss of $9,907,000 ($0.20 per share) for ...
- April 24, 2009
BELLUS announces Chief Financial Officer to depart effective May 22, 2009
LAVAL, QC, April 24 /CNW Telbec/ - BELLUS Health announced today that Vice President, Finance and Chief Financial Officer Mr. Mariano Rodriguez will depart from the Company, effective May 22, 2009. ...
- April 16, 2009
BELLUS Health inc. announces completion of first tranche of financing
LAVAL, QC, April 16 /CNW Telbec/ - Further to the press releases of March 31 and April 8, 2009, BELLUS Health Inc. ("BELLUS Health") (TSX: BLU) is pleased to announce the completion of the first tranche of its previously ...
- April 8, 2009
BELLUS Health Inc. provides an update on the financing and the restructuring of existing notes
LAVAL, QC, April 8 /CNW Telbec/ - Further to the press release of March 31, 2009, BELLUS Health Inc. ("BELLUS Health") (TSX: BLU) is providing additional information regarding the announced financing and restructuring of ...
- March 31, 2009
BELLUS Health Inc. provides financing update and announces restructuring of existing notes
LAVAL, QC, March 31 /CNW Telbec/ - BELLUS Health Inc. (the "Company") (TSX: BLU) announced today that it has entered into binding letter agreements with each of Vitus Investments III Private Limited, a corporation whose shares ...
- March 24, 2009
BELLUS Health provides financing update
LAVAL, QC, March 24 /CNW Telbec/ - Further to the press release issued on February 26, 2009, BELLUS Health Inc. (TSX: BLU) reports that, notwithstanding the expiration of the previously announced financing commitments of up to $20 ...
- March 12, 2009
BELLUS Health announces staff reductions to lower operating expenses
LAVAL, QC, March 12 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) announced today that it has reduced its workforce by approximately 45%, effective immediately. It is expected that this current reduction in the ...
- February 26, 2009
BELLUS Health reports results for the fourth quarter of 2008
LAVAL, QC, Feb. 26 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) reported today its results for the fourth quarter ended December 31, 2008, and commented on the status of its efforts to secure additional financing. ...
- December 17, 2008
BELLUS Health announces formal notice to voluntarily delist from NASDAQ
BELLUS Health Successfully Completed and Closed the Amendment of the -------------------------------------------------------------------- Trust Indenture Governing the November 2006 Notes ...
- December 5, 2008
BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
BELLUS Health Receives NASDAQ Deficiency Notice Relating to Market Value ------------------------------------------------------------------------ LAVAL, QC, Dec. 5 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: ...
- November 13, 2008
BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
LAVAL, QC, Nov. 13 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces today that it has received approval from the NASDAQ Listing Qualifications Staff of The NASDAQ Stock Market LLC (the "Staff") to transfer ...
- November 10, 2008
BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
LAVAL, QC, Nov. 10 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) reports results for the third quarter ended September 30, 2008. For the three-month period ended September 30, 2008, the net loss amounted to ...
- November 6, 2008
BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
Presentation will be Web cast live LAVAL, QC, Nov. 6 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces today that on Tuesday, November 11, Mr. Gary Schmid, President ...
- October 21, 2008
BELLUS Health provides update on activities
LAVAL, QC, Oct. 21 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) is pleased to provide an update on its branded nutraceutical and pharmaceutical activities. The commercial activities surrounding sales of its ...
- October 15, 2008
BELLUS Health Receives Nasdaq Deficiency Notice Relating to Market Value
LAVAL, QC, Oct. 15 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces that it received a Nasdaq Staff Deficiency Letter dated October 10, 2008, stating that, for 10 consecutive trading days, the market ...
- September 2, 2008
A new generation of memory protection To access a multimedia version of this release, please visit http://www.ovos.com/vivimind/index.htm ...
- August 12, 2008
Correction from source - BELLUS Health
LAVAL, QC, Aug. 12 /CNW Telbec/ - A correction from source is issued with respect to the BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) release issued on August 5, 2008, in which a reference was made to the Company's number of ...
- August 5, 2008
LAVAL, QC, Aug. 5 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announced meaningful progress in both its nutraceutical and pharmaceutical programs and reported results for the second quarter ended ...
- July 17, 2008
BELLUS Health announces closing of Innodia acquisition
Company announces change to senior management team -------------------------------------------------- LAVAL, QC, July 17 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; ...
- July 16, 2008
BELLUS Health signs agreement to acquire Innodia
LAVAL, QC, July 16 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) announced today that it has signed a definitive agreement to purchase capital stock of Innodia Inc. This will ...
- May 15, 2008
BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
Presentation will be Web cast live LAVAL, QC, May 15 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) announces today that on Monday, May 19, ...
- May 5, 2008
BELLUS HEALTH reports results for first quarter of fiscal 2008
LAVAL, QC, May 5 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU, formerly known as Neurochem Inc.) reported results for the first quarter ended March 31, 2008. The Company reported a net loss of $12,902,000 ...
- April 15, 2008
Neurochem Annual and Special Meeting web cast live LAVAL, QC, April 15 /CNW Telbec/ - At the Annual and Special meeting of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), shareholders will be asked to ...
LAVAL, QC, April 11 /CNW Telbec/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem Inc., invites the news media to the Annual and Special Meeting of Shareholders to be held on Tuesday, ...
- April 11, 2008
Media advisory - Neurochem's Annual and Special Meeting of Shareholders April 15, 2008
LAVAL, QC, April 11 /CNW Telbec/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem Inc., invites the news media to the Annual and Special Meeting of Shareholders to be held on Tuesday, ...
Neurochem Annual and Special Meeting of shareholders
Neurochem will host a live Web conference on Tuesday, April 15, 2008, at ------------------------------------------------------------------------ 10:00 AM ET ...
- March 13, 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
ECUBLENS, SWITZERLAND, March 13 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company is taking new initiatives to ...
- February 21, 2008
Neurochem announces departure of two members of management team
LAVAL, QC, Feb. 21 /CNW Telbec/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior ...
- February 20, 2008
Neurochem will host a conference call Thursday, February 21, 2008, at 8:30 A.M. ET. LAVAL, QC, Feb. 20 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) ...
- February 11, 2008
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
LAVAL, QC, Feb. 11 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary ...
- January 30, 2008
Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
LAVAL, QC, Jan. 30 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Mr. Gary Schmid will join Neurochem, effective February 4, 2008, and will serve as Chief Executive Officer (CEO) of the new ...
- January 3, 2008
Neurochem to present at JPMorgan Healthcare Conference
LAVAL, QC, Jan. 3 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Thursday, January 10, 2008, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem's overall strategy at the ...
- December 14, 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
ECUBLENS, Switzerland, Dec. 14 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Committee for Medicinal Products for Human ...
- December 6, 2007
ECUBLENS, Switzerland, Dec. 6 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company has received an acknowledgement ...
- November 30, 2007
Neurochem announces departure of Dr. Philippe Calais, President, Global Business
LAVAL, QC, Nov. 30 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announces the departure of Philippe Calais, PhD. Pharm., Neurochem's President, Global Business. Dr. Calais joined Neurochem in 2003, and is ...
- November 8, 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem will host a live web conference today November 8, 2007, at 8:30 AM ET LAVAL, QC, Nov. 8 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) ...
- November 7, 2007
Neurochem reports results for third quarter of fiscal 2007
Neurochem will host a live web conference Thursday November 8, 2007, at 8:30 AM ET. LAVAL, QC, Nov. 7 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) ...
- August 28, 2007
Neurochem provides information on cash position
LAVAL, QC, Aug. 28 /CNW Telbec/ - Following the issuance of a press release on August 26, 2007, announcing results from the tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial and the subsequent ...
- August 26, 2007
Neurochem Announces results from Tramiprosate (ALZHEMED(TM)) North American Phase III Clinical Trial
Neurochem will host a conference call tomorrow August 27, 2007, at 8:30 AM EDT. LAVAL, QC, Aug. 26 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) ...
- August 9, 2007
Neurochem reports results for second quarter of fiscal 2007
Neurochem will host a conference call, August 9, 2007, at 5:00 PM EDT. LAVAL, QC, Aug. 9 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) reported results for the second quarter ended June 30, 2007. The Company ...
- July 24, 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Neurochem to meet with FDA to discuss statistical models for the completed North American Phase III clinical trial LAVAL, QC, July 24 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) ...
- July 17, 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
ECUBLENS, Switzerland, July 17 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the Company has received a second approvable ...
- June 26, 2007
Neurochem to present at Jefferies Healthcare Conference
LAVAL, QC, June 26 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, June 27, 2007, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem's overall strategy and ...
- June 22, 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
LAVAL, QC, June 22 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) has issued an update on the progress made since announcing in April 2007 that adjustments would be required to arrive at a reliable statistical model for ...
- June 21, 2007
LAVAL, QC, June 21 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces that it has received a third recommendation from the European Data Safety Monitoring Board (DSMB) to continue its ongoing European Phase III ...
- June 18, 2007
LAVAL, QC, June 18 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced today that it has given notice of mandatory conversion into common shares of Neurochem of the full remaining balance of the US$40 million of 5% ...
- June 11, 2007
WASHINGTON, DC, June 11 /CNW Telbec/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III ...
- June 7, 2007
ECUBLENS, SWITZERLAND, June 7 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that the New England Journal of Medicine (NEJM) ...
- June 5, 2007
LAVAL, QC, June 5 /CNW Telbec/ - Neurochem Inc. ("Neurochem") (NASDAQ: NRMX, TSX: NRM) announced today that, in connection with its previously announced private placement of US$80 million aggregate principal amount of ...
- May 8, 2007
The Neurochem AGM will be web cast live LAVAL, QC, May 8 /CNW Telbec/ - At its annual general meeting of shareholders, Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) will highlight fast ...
Neurochem reports results for first quarter of fiscal 2007
LAVAL, QC, May 8 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) reported results for the first quarter ended March 31, 2007. The Company reported a net loss of $24,618,000 ($0.63 per share) for the quarter, compared ...
- May 7, 2007
Media advisory - Neurochem's Annual General Meeting of Shareholders on May 8, 2007
MONTREAL, May 7 /CNW Telbec/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem Inc., invites the news media to the Annual General Meeting of Shareholders to be held on Tuesday, May 8, 2007, at ...
- May 2, 2007
LAVAL, QC, May 2 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced today a private placement of US$80 million aggregate principal amount of convertible notes, consisting of US$40 million of 6% senior ...
- April 19, 2007
LAVAL, QC, April 19 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces that the database for the North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease ...
- April 11, 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
ECUBLENS, Switzerland, April 11 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces that it received notification from the ...
- February 21, 2007
Neurochem reports results for fourth quarter and fiscal year 2006
Neurochem will host a conference call Thursday, February 22, 2007, at 8:30 A.M. ET. LAVAL, QC, Feb. 21 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) ...
- February 13, 2007
LAVAL, QC, Feb. 13 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces that it has received a second recommendation from the European Data Safety Monitoring Board (DSMB) to continue its ongoing European Phase III ...
- February 1, 2007
LAVAL, QC, Feb. 1 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announces the completion of its 18-month North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease ...